Screener
BridgeBio Pharma BBIO Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturities of marketable securities | 10,000 | — |
| Payment for an intangible asset | — | (1,595) |
| Purchases of property and equipment | (69) | — |
| Net cash used in investing activities | (42,735) | (1,595) |
| Financing activities: | ||
| Proceeds from issuance of 2033 Notes | 632,500 | — |
| Issuance costs and discounts associated with 2033 Notes | (12,796) | — |
| Proceeds from issuance of 2031 Notes | — | 575,000 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's investing cash flow?
- BridgeBio Pharma (BBIO) reported investing cash flow of -$42.74M in Q1 2026.
- How has BridgeBio Pharma's investing cash flow changed year-over-year?
- BridgeBio Pharma's investing cash flow decreased by 2579.3% year-over-year, from -$1.6M to -$42.74M.
- What is the long-term trend for BridgeBio Pharma's investing cash flow?
- Over 2 years (2022 to 2024), BridgeBio Pharma's investing cash flow has grown at a -62.4% compound annual growth rate (CAGR), from $453.15M to $64.02M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about BridgeBio Pharma's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude